Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SURAJ MULEY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1417056730
CMS profile
64124
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$249,067.84

278 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
CSL Behring $73,648.36 82
Alexion Pharmaceuticals, Inc. $68,627.09 57
ARGENX US, INC. $45,611.15 52
Takeda Pharmaceuticals U.S.A., Inc. $29,465.26 33
CATALYST PHARMACEUTICALS, INC. $11,559.03 13
Grifols USA, LLC $7,335.50 9
UCB, Inc. $6,433.74 11
Horizon Therapeutics plc $4,355.67 8
Janssen Global Services, LLC $687.90 1
Biogen, Inc. $467.40 4
Celgene Corporation $340.73 3
Genentech, Inc. $281.67 3
Grifols Shared Services North America, Inc. $137.39 1
EMD Serono, Inc. $116.95 1

Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SURAJ MULEY

NPI 1417056730 · CMS profile ID 64124

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417056730?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SURAJ MULEY, NPI 1417056730, CMS profile ID 64124. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417056730?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SURAJ MULEY, NPI 1417056730, CMS profile ID 64124. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417056730?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SURAJ MULEY, NPI 1417056730, CMS profile ID 64124, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1417056730?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

278 matching records · $249,067.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 278 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 278.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Grifols USA, LLC $428.0811/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965229541 CMS
Alexion Pharmaceuticals, Inc. $1,020.0011/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915628449 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,250.0010/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745683 CMS
ARGENX US, INC. $677.0910/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631595 CMS
ARGENX US, INC. $247.9010/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631597 CMS
Alexion Pharmaceuticals, Inc. $2,550.0010/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915598609 CMS
ARGENX US, INC. $612.2010/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631591 CMS
ARGENX US, INC. $281.4010/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631593 CMS
Alexion Pharmaceuticals, Inc. $96.1410/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915827303 CMS
Takeda Pharmaceuticals U.S.A., Inc. $43.7910/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745655 CMS
Takeda Pharmaceuticals U.S.A., Inc. $70.3410/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745659 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.6310/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745663 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.5710/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745667 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.9410/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745671 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.6310/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745673 CMS
Takeda Pharmaceuticals U.S.A., Inc. $59.0010/21/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745679 CMS
Alexion Pharmaceuticals, Inc. $131.6910/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915323165 CMS
Grifols USA, LLC $387.5010/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965229537 CMS
Grifols USA, LLC $18.3110/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918701753 CMS
Grifols USA, LLC $108.0810/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918724525 CMS
ARGENX US, INC. $5,750.0010/14/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631545 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.0010/12/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745639 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.5010/12/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745643 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.6110/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745647 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.6810/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745651 CMS
Horizon Therapeutics plc $47.9210/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937664255 CMS
Horizon Therapeutics plc $23.9610/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937664257 CMS
Horizon Therapeutics plc $62.2910/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937664259 CMS
Horizon Therapeutics plc $23.9610/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937664261 CMS
Horizon Therapeutics plc $12.5010/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937664263 CMS
Horizon Therapeutics plc $4,000.0010/08/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937664265 CMS
Alexion Pharmaceuticals, Inc. $130.2510/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914746701 CMS
Horizon Therapeutics plc $110.2910/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937664253 CMS
Alexion Pharmaceuticals, Inc. $2,550.0010/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915033097 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,750.0010/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745635 CMS
Alexion Pharmaceuticals, Inc. $91.1310/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915649033 CMS
CSL Behring $2,970.0010/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940838157 CMS
CSL Behring $5.6310/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940838159 CMS
Celgene Corporation $105.6310/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932490857 CMS
ARGENX US, INC. $26.4309/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631675 CMS
ARGENX US, INC. $22.5009/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631679 CMS
ARGENX US, INC. $2,000.0009/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631683 CMS
ARGENX US, INC. $89.9209/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631677 CMS
ARGENX US, INC. $22.5009/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631681 CMS
ARGENX US, INC. $2,000.0009/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951631685 CMS
Alexion Pharmaceuticals, Inc. $22.6609/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914968097 CMS
CSL Behring $102.7109/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940838155 CMS
Biogen, Inc. $82.2909/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923386965 CMS
Takeda Pharmaceuticals U.S.A., Inc. $95.5409/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955745631 CMS
CSL Behring $4,620.0009/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940838153 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $238,651.17 345
PY2020 $58,272.54 59
PY2021 $73,200.32 92
PY2022 $249,067.84 278
PY2023 $336,541.64 319
PY2024 $344,522.08 386
PY2025 $412,787.88 405

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $638,715.37 30
PY2024 Principal investigator $54,903.49 3
PY2023 Principal investigator $29,152.25 2
PY2022 Principal investigator $17,302.50 3
PY2021 Principal investigator $189,151.70 32
PY2020 Principal investigator $78,931.56 14
PY2019 Recipient $17,955.00 1
PY2019 Principal investigator $64,325.84 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $1,500.00 12/08/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Osborn Med Ct
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226136132
Principal investigator 1 ARGENX US, INC. $15.66 12/01/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237142340
Principal investigator 1 Novartis Pharmaceuticals Corporation $369,837.37 11/19/2025 Non-covered Recipient Entity
HONOR HEALTH RESEARCH INSTITUTE
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190309330
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,495.86 11/06/2025 Non-covered Recipient Entity
HONOR HEALTH RESEARCH INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190309332
Principal investigator 1 Novartis Pharmaceuticals Corporation $158,319.18 11/01/2025 Non-covered Recipient Entity
HONOR HEALTH RESEARCH INSTITUTE
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190312211
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,150.00 10/22/2025 Non-covered Recipient Entity
HONOR HEALTH RESEARCH INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190312217
Principal investigator 1 Alexion Pharmaceuticals, Inc. $100.00 10/14/2025 Covered Recipient Teaching Hospital
Methodist Hospital Of Sacramento
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185552409
Principal investigator 1 ARGENX US, INC. $2,330.40 09/10/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142264
Principal investigator 1 ARGENX US, INC. $1,068.20 09/10/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142268
Principal investigator 1 ARGENX US, INC. $3,128.40 09/03/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142245
Principal investigator 1 ARGENX US, INC. $2,100.00 09/03/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142253
Principal investigator 1 ARGENX US, INC. $1,500.00 09/03/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142257
Principal investigator 1 ARGENX US, INC. $2,000.00 09/03/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142261
Principal investigator 1 ARGENX US, INC. $131.30 08/27/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142250
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 08/25/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Osborn Med Ct
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226136082
Principal investigator 1 ARGENX US, INC. $3,000.00 07/16/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237142330
Principal investigator 1 ARGENX US, INC. $12,000.00 07/16/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237142335
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 07/01/2025 Covered Recipient Teaching Hospital
HONORHEALTH SCOTTSDALE OSBORN MED CT
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223266783
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,447.00 06/24/2025 Covered Recipient Teaching Hospital
HONORHEALTH DEER VALLEY MED CTR
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223266771
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,120.00 06/24/2025 Covered Recipient Teaching Hospital
HONORHEALTH DEER VALLEY MED CTR
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223266773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,052.00 06/24/2025 Covered Recipient Teaching Hospital
HONORHEALTH DEER VALLEY MED CTR
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223266775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,312.00 06/01/2025 Covered Recipient Teaching Hospital
HONORHEALTH SCOTTSDALE OSBORN MED CT
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223266781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,312.00 04/01/2025 Covered Recipient Teaching Hospital
HONORHEALTH SCOTTSDALE OSBORN MED CT
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223266777
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 04/01/2025 Covered Recipient Teaching Hospital
HONORHEALTH SCOTTSDALE OSBORN MED CT
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223266779
Principal investigator 1 ARGENX US, INC. $1,000.00 03/07/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142277
Principal investigator 1 ARGENX US, INC. $12,000.00 03/07/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142282
Principal investigator 1 ARGENX US, INC. $1,323.00 03/07/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142287
Principal investigator 1 ARGENX US, INC. $8,142.40 03/07/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142290
Principal investigator 1 ARGENX US, INC. $2,250.00 03/07/2025 Covered Recipient Teaching Hospital
Honorhealth Scottsdale Thompson Peak
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237142295
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,810.60 01/31/2025 Non-covered Recipient Entity
HONOR HEALTH RESEARCH INSTITUTE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190312213